Ventus Therapeutics has raised a $100 million series B to take small molecules against traditionally undruggable targets into clinical trials. The pipeline features NLRP3 inhibitors that Ventus is pitching as best-in-class candidates in the competitive inflammasome space.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,